Vividion is a developer of a novel drug discovery platform designed to offer transformative treatments to patients with serious illnesses.
Vividion is a biotechnology company focused on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome-wide drug and target discovery. Making accessible the broad set of proteins expressed in human cells, the company’s platform was spun out of the labs of Vividion’s scientific founders, a team of experts in chemical biology and synthetic chemistry from The Scripps Research Institute in La Jolla, CA. Vividion is committed to advancing and applying its pioneering synthetic and proteomic chemistry platforms to create therapeutics that will make a transformative difference in patients.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 24, 2021 | Series C | $135M | 2 | — | — | Detail |
Apr 30, 2019 | Series B | $82M | 2 | — | — | Detail |
Feb 2, 2017 | Series A | $50M | 2 | ARCH Venture Partners Versant Ventures | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
ARCH Venture Partners | — | Series C |
Versant Ventures | — | Series C |